Trillium develops blood cancer drugs designed to boost a person’s immune system to detect and destroy cancer cells.
More than 1 million people worldwide were diagnosed with a form of blood cancer in 2020, making up almost 6 percent of all cancer diagnoses. Roughly 700,000 people died of blood cancer the same year, Pfizer said in a news release. Trillium said it expects the acquisition will allow its drugs to reach patients faster.
Pfizer invested $25 million in Trillium in September 2020. The completion of the acquisition is subject to court and regulatory approval.
Shares of Trillium nearly tripled Aug. 23 after the deal was announced, according to MarketWatch.
Read Pfizer’s full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
